TacticScaleWhat Prestige Consumer Healthcare Does & How It Makes Money (PBH)
Updated October 2026 · reflects Prestige Consumer Healthcare's latest reported financials
Maker of well-known over-the-counter health and personal care brands. It makes money by developing, making, and selling branded OTC health and personal care products to mass merchandisers, drug, food, dollar, convenience, and club stores, and through e-commerce channels.
How Prestige Consumer Healthcare makes money
It makes money by developing, making, and selling branded OTC health and personal care products to mass merchandisers, drug, food, dollar, convenience, and club stores, and through e-commerce channels.
What Prestige Consumer Healthcare does
Prestige Consumer Healthcare, formerly Prestige Brands Holdings, is a portfolio company of over-the-counter health and personal care brands. Its lineup covers many everyday needs: BC and Goody's analgesic powders, Clear Eyes and TheraTears eye care, Chloraseptic and Luden's for sore throats and coughs, Dramamine for motion sickness, Debrox for ear wax, Compound W for warts, Monistat and Summer's Eve for women's health, Fleet laxatives, Gaviscon for stomach upset, Nix lice treatments, Boudreaux's Butt Paste for diaper rash, and DenTek oral care. The company reports two segments, North American OTC Healthcare and International OTC Healthcare, and its international brands include Fess nasal saline and Hydralyte oral rehydration. It sells through mass merchandisers, drug, food, dollar, convenience, and club stores, as well as e-commerce. Founded in 1996, it is headquartered in Tarrytown, New York.
Products & services
- Clear Eyes
- Dramamine
- Monistat
- Summer's Eve
- Chloraseptic
- DenTek
What is Prestige Consumer Healthcare worth?
On an owner-earnings DCF, Prestige Consumer Healthcare's most-likely value is about $64 versus a recent price near $48 (33% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$45) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 8.4× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Perrigo (PRGO) · The Procter & Gamble (PG) · Coty (COTY) · Colgate-Palmolive (CL)